Glenmark Pharma

Which are the latest news on Glenmark Pharma?

Why is Glenmark Pharmaceuticals Ltd. falling/rising?

As of 05-Sep, Glenmark Pharmaceuticals Ltd. is seeing a stock price decline to Rs 2,427.00, down -1.29%, due to underperformance against its sector and reduced investor interest. Recent quarterly results show significant drops in profit metrics, contributing to negative sentiment despite strong long-term performance.

As of 05-Sep, Glenmark Pharmaceuticals Ltd. is experiencing a decline in its stock price, currently at Rs 2,427.00, which reflects a change of -31.8 (-1.29%). This decrease can be attributed to several factors. <BR><BR>Firstly, the stock has underperformed its sector today by -0.84%, indicating that it is not keeping pace with its peers. Additionally, there has been a notable drop in investor participation, with delivery volume falling by -16.04% compared to the 5-day average, suggesting reduced interest from investors. <BR><BR>Despite the stock's strong performance over longer periods, such as a 21.92% return over the past year and a significant 177.5% increase in profits, recent quarterly results have shown concerning trends. The profit before tax (PBT) has fallen by -39.0% compared to the previous four-quarter average, and the profit after tax (PAT) has decreased by -31.6% in the same context. These flat results could be contributing to the current negative sentiment surrounding the stock.<BR><BR>While the company maintains a strong ability to service debt and has high institutional holdings, the immediate performance indicators and recent earnings results appear to be influencing the stock's downward movement.

Who are in the management team of Glenmark Pharma?

The management team of Glenmark Pharma includes Glenn Saldanha (Chairman/Executive Director), Cheryl Pinto (Executive Director), and V S Mani (Executive Director & Group CFO), along with several independent and non-executive directors who guide the company's strategic direction.

The management team of Glenmark Pharma includes the following key members:<BR><BR>1. **Glenn Saldanha** - Chairman / Executive Director<BR>2. **Cheryl Pinto** - Executive Director (Corporate)<BR>3. **V S Mani** - Executive Director & Group CFO<BR><BR>Additionally, the Board of Directors features several independent and non-executive directors:<BR><BR>- **B E Saldanha** - Non-Executive Director<BR>- **Rajesh Desai** - Independent Non-Executive Director<BR>- **Devendra Raj Mehta** - Independent Non-Executive Director<BR>- **Bernard Munos** - Independent Non-Executive Director<BR>- **Brian W Tempest** - Independent Non-Executive Director<BR>- **Sridhar Gorthi** - Independent Non-Executive Director<BR>- **Sona Saira Ramasastry** - Independent Non-Executive Director<BR>- **Dipankar Bhattacharjee** - Independent Non-Executive Director<BR>- **V R Iyer** - Independent Non-Executive Director<BR><BR>This team plays a crucial role in guiding the strategic direction of the company.

What does Glenmark Pharma do?

Glenmark Pharmaceuticals Ltd. is a mid-cap company involved in the discovery, development, manufacturing, and marketing of pharmaceutical products. As of June 2026, it reported net sales of ₹4,018 Cr and a net profit of ₹483 Cr, with a market cap of ₹70,148 Cr.

Overview: <BR>Glenmark Pharmaceuticals Ltd. is a mid-cap company in the Pharmaceuticals & Biotechnology industry, engaged in the discovery, development, manufacture, and marketing of pharmaceutical products, including new chemical and biological entities.<BR><BR>History: <BR>Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 4,018 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 483 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 70,148 Cr (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 23.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.20% <BR>Debt-Equity: -0.06 <BR>Return on Equity: 26.86% <BR>Price to Book: 6.76<BR><BR>Contact Details: <BR>Address: B/2 Mahalaxmi Chambers, 22 Bhulabhai Desai Road Mumbai Maharashtra : 400026 <BR>Tel: 91-22-40189999 <BR>Email: complianceofficer@glenmarkpharma.co <BR>Website: http://www.glenmarkpharma.com

Who are the peers of the Glenmark Pharma?

Glenmark Pharma's peers include Laurus Labs, Lupin, Dr Reddy's Labs, Mankind Pharma, Aurobindo Pharma, Biocon, Alkem Lab, Abbott India, and Glaxosmi. In terms of management risk, growth, and capital structure, Glenmark Pharma is rated as having good management risk and capital structure, with average growth compared to its peers.

Peers: Glenmark Pharma's peers are Laurus Labs, Lupin, Dr Reddy's Labs, Mankind Pharma, Aurobindo Pharma, Biocon, Alkem Lab, Abbott India, and Glaxosmi. Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Lupin, Mankind Pharma, Abbott India, and Glaxosmi. Pharma, while Good management risk is found at Laurus Labs, Dr Reddy's Labs, Glenmark Pharma, Alkem Lab, and Anthem Bioscienc. Average management risk is noted at Aurobindo Pharma and Biocon. For Growth, Excellent growth is seen at Lupin and Anthem Bioscienc, while Good growth is noted at Mankind Pharma, and Average growth is found at Dr Reddy's Labs, Glenmark Pharma, and Biocon. Below Average growth is observed at Laurus Labs, Aurobindo Pharma, and Alkem Lab. In terms of Capital Structure, Excellent capital structure is present at Dr Reddy's Labs, Mankind Pharma, Aurobindo Pharma, Alkem Lab, Abbott India, and Glaxosmi. Pharma, while Good capital structure is noted at Glenmark Pharma and Average at Laurus Labs and Biocon.<BR><BR>Return Snapshot: Laurus Labs has the highest 1-year return at 122.69%, while Abbott India has the lowest at -17.91%. Glenmark Pharma's 1-year return is 29.39%, which is significantly higher than Abbott India's but lower than Laurus Labs'. Additionally, the six-month return is negative for Lupin, Dr Reddy's Labs, Biocon, Alkem Lab, and Abbott India.

How big is Glenmark Pharma?

As of 31st August, Glenmark Pharmaceuticals Ltd. has a market capitalization of 70,148.00 Cr, with net sales of 17,736.56 Cr and a net profit of 1,797.89 Cr reported in the latest four quarters. The company has shareholder's funds of 10,512.11 Cr and total assets of 18,661.26 Cr as of March 2026.

As of 31st August, Glenmark Pharmaceuticals Ltd. has a market capitalization of 70,148.00 Cr, categorizing it as a Mid Cap company.<BR><BR>In the latest four quarters, Glenmark Pharmaceuticals reported net sales of 17,736.56 Cr and a net profit of 1,797.89 Cr.<BR><BR>For the latest annual period ending in March 2026, the company had shareholder's funds amounting to 10,512.11 Cr and total assets of 18,661.26 Cr.

Should I buy, sell or hold Glenmark Pharmaceuticals Ltd.?

When is the next results date for Glenmark Pharmaceuticals Ltd.?

The next results date for Glenmark Pharmaceuticals Ltd. is 31 July 2026.

The next results date for Glenmark Pharmaceuticals Ltd. is scheduled for 31 July 2026.

Are Glenmark Pharmaceuticals Ltd. latest results good or bad?

Glenmark Pharmaceuticals Ltd.'s latest results show strong year-on-year growth with a net profit increase of 6,381.94% and net sales up 15.80%. However, there are concerns due to sequential declines in both profit and sales, indicating potential volatility in performance.

Glenmark Pharmaceuticals Ltd.'s latest results present a mixed picture. For the quarter ending March 2026, the company reported a net profit of ₹301.41 crores, which reflects a significant year-on-year increase of 6,381.94%. However, this represents a decline of 25.25% compared to the previous quarter, raising concerns about the sustainability of its recent performance.<BR><BR>Net sales for the same quarter were ₹3,770.59 crores, showing a 15.80% increase year-on-year, but a decrease of 3.33% from the previous quarter. This sequential decline follows an unusually strong performance in Q3 FY26, which had benefited from one-time gains.<BR><BR>Operating margins also contracted to 20.28%, down from 22.37% in the previous quarter, indicating some pressure on profitability. Despite these challenges, the company's return on capital employed (ROCE) reached an impressive 40.16%, the highest level recorded in recent periods, suggesting strong operational efficiency.<BR><BR>Overall, while Glenmark's year-on-year growth is commendable, the sequential declines in both net profit and sales indicate potential volatility and questions about the underlying business momentum. Investors may want to consider these factors when evaluating the company's performance.

Is Glenmark Pharma overvalued or undervalued?

As of November 17, 2025, Glenmark Pharma is considered undervalued with a PE ratio of 23.47 and strong growth potential, outperforming peers like Sun Pharma and Cipla, and has delivered a 21.44% return over the past year compared to the Sensex's 9.50%.

As of 17 November 2025, Glenmark Pharma's valuation grade has moved from expensive to attractive, indicating a shift in market perception. The company is currently considered undervalued. Key ratios supporting this assessment include a PE ratio of 23.47, an EV to EBITDA of 12.50, and a PEG ratio of 0.04, which suggests strong growth potential relative to its price.<BR><BR>In comparison to its peers, Glenmark Pharma's valuation metrics stand out; for instance, Sun Pharma has a significantly higher PE ratio of 36.69, while Cipla, another attractive peer, has a PE of 22.81. This positions Glenmark favorably within the industry, particularly given its robust ROCE of 44.14% and ROE of 23.46%. Additionally, Glenmark's stock has outperformed the Sensex over the past year, with a return of 21.44% compared to the Sensex's 9.50%, reinforcing the attractiveness of its current valuation.

How has been the historical performance of Glenmark Pharma?

Glenmark Pharma's historical performance shows significant fluctuations, with net sales increasing to 13,321.74 Cr in Mar'25 after a dip in Mar'23, and a recovery in profit after tax to 1,047.14 Cr in Mar'25 from a loss of 1,830.85 Cr in the previous year. Despite negative cash flow from operating activities in Mar'25, the company demonstrates a recovery trajectory following a challenging period.

Answer:<BR>The historical performance of Glenmark Pharma shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Glenmark Pharma's net sales increased from 10,640.97 Cr in Mar'20 to 13,321.74 Cr in Mar'25, with a notable dip in Mar'23 at 12,990.11 Cr. Total operating income followed a similar trend, reaching 13,321.74 Cr in Mar'25. The total expenditure, excluding depreciation, rose from 8,279.66 Cr in Mar'19 to 10,970.36 Cr in Mar'25. Operating profit (PBDIT) saw fluctuations, peaking at 2,595.16 Cr in Mar'23 before declining to 2,465.10 Cr in Mar'25. Profit before tax was 1,399.21 Cr in Mar'25, recovering from a low of 36.50 Cr in Mar'24. The profit after tax turned positive at 1,047.14 Cr in Mar'25 after a significant loss of 1,830.85 Cr in the previous year. The earnings per share (EPS) rebounded to 37.1 in Mar'25 from a negative EPS of -53.21 in Mar'24. Total assets increased to 14,925.44 Cr in Mar'25, while total liabilities also rose to 14,925.44 Cr, indicating a balanced growth in the company’s financial structure. Cash flow from operating activities was negative at -827.00 Cr in Mar'25, contrasting with a positive cash flow of 782.00 Cr in Mar'24. Overall, Glenmark Pharma's financial performance reflects a recovery trajectory in 2025 after a challenging previous year.

Is Glenmark Pharma technically bullish or bearish?

As of September 10, 2025, Glenmark Pharma's trend is mildly bullish, supported by daily moving averages and weekly Bollinger Bands, but tempered by mixed signals from the MACD and OBV.

As of 10 September 2025, the technical trend for Glenmark Pharma has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating bullish momentum and the weekly Bollinger Bands also showing bullish signals. However, the weekly MACD is mildly bearish and the KST is bullish on a weekly basis but mildly bearish on a monthly basis, suggesting some mixed signals. The Dow Theory indicates a mildly bullish stance on the weekly chart, while the OBV shows a mildly bearish trend. Overall, the strength of the bullish sentiment is tempered by the mixed indicators, particularly on the weekly timeframe.

Who are the top shareholders of the Glenmark Pharma?

The top shareholders of Glenmark Pharma include the Saldanha Family Trust with 45.45%, institutional investors holding 36.02% (including 25 mutual fund schemes at 12.86% and 347 FIIs at 23.16%), and individual investors with 12.32%. HDFC Mutual Fund is the largest public shareholder with a 4.27% stake.

The top shareholders of Glenmark Pharma include the Saldanha Family Trust, which holds the largest stake at 45.45%. The company also has significant institutional backing, with 25 mutual fund schemes collectively holding 12.86% and 347 foreign institutional investors (FIIs) holding 23.16%. Additionally, HDFC Mutual Fund, specifically through the HDFC Nifty Large Midcap 250 Index fund, is the highest public shareholder with a 4.27% stake. Individual investors collectively own 12.32% of the company.

Has Glenmark Pharma declared dividend?

Yes, Glenmark Pharmaceuticals has declared a 250% dividend, amounting to ₹2.5 per share, with an ex-date of September 13, 2024. The company has shown strong total returns over various periods, particularly in the long term.

Glenmark Pharmaceuticals Ltd. has declared a 250% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 250%<BR>- Amount per share: 2.5<BR>- Ex-date: 13 Sep 24<BR><BR>Dividend Yield: 0.16%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 3.97%, with no dividend return, resulting in a total return of 3.97%.<BR><BR>Over the past year, the price return was 31.68%, with a dividend return of 0.21%, leading to a total return of 31.89%.<BR><BR>In the 2-year period, the price return was 152.58%, with a dividend return of 0.78%, culminating in a total return of 153.36%.<BR><BR>For the 3-year period, the price return was 305.84%, with a dividend return of 2.04%, resulting in a total return of 307.88%.<BR><BR>In the last 4 years, the price return was 159.41%, with a dividend return of 1.50%, giving a total return of 160.91%.<BR><BR>Over the 5-year period, the price return was 295.81%, with a dividend return of 2.87%, leading to a total return of 298.68%.<BR><BR>Overall, Glenmark Pharma has declared a substantial dividend, and the total returns over various periods indicate strong price appreciation, particularly over the longer term, suggesting a positive performance trend for the company.